Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Zeo ScientifiX ( (ZEOX) ) is now available.
On July 9, 2025, ZEO ScientifiX announced an expansion initiative in response to Florida’s new SB-1768 stem cell law, which allows the use of non-FDA-approved stem cell therapies. The company launched a new website and formed agency partnerships to address the anticipated demand in the biologics market. ZEO aims to lead the market with its proprietary biologics platform, educational initiatives, and compliance focus, positioning itself as a key player in the emerging regenerative medicine market in Florida and potentially other states.
More about Zeo ScientifiX
ZEO ScientifiX, Inc. is a clinical-stage biopharmaceutical company focused on developing innovative biological therapeutics. The company is committed to advancing regenerative medicine and biologic therapeutics, offering proprietary products such as Zofin™ and Patient Pure X™. These products are manufactured in an FDA-registered, cGMP-compliant laboratory, with a focus on setting industry standards and educating physicians to improve patient care.
Average Trading Volume: 6,413
Technical Sentiment Signal: Hold
Current Market Cap: $12.84M
Learn more about ZEOX stock on TipRanks’ Stock Analysis page.